Mankind Pharma

Mankind Pharma

2,589.50
-9.50
(-0.37%)
Market Cap
1,06,876.11 Cr
EPS
49.28
PE Ratio
61.82
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
3,054.80
52 Week Low
1,901.05
PB Ratio
7.49
Debt to Equity
0.37
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+68.75 %
+68.75 %
Hold
Hold+18.75 %
+18.75 %
Sell
Sell+12.50 %
+12.50 %

Company News

View All News
Caret
neutral
Mankind Pharma Limited received a request from Ayushi and Poonam Estates LLP to reclassify their shareholding from Promoter and Promoter Group category to Public category. The LLP was previously classified as Promoter Group because it was entirely owned by Mrs. Poonam Juneja and Mrs. Ayushi Juneja Sikri, both immediate relatives of Mankind's promoters. However, following a complete transfer of ownership through a deed of admission, the LLP is now owned and controlled by Chalet Hotels Limited and Sonmil Industries Private Limited through their respective nominees - Mr. Shwetank Singh and Ms. Karuna Nasta as designated partners. The LLP confirms it does not hold any shares in Mankind Pharma, does not exercise control over the company's affairs, has no representation on the board, and possesses no special rights. The request will be placed before Mankind Pharma's board of directors for consideration along with other necessary approvals as per SEBI listing regulations.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,692.00
#1 4,05,967.48
35.24
#1 54,729.00
12.06
#1 10,980
-18.99
52.71
6,618.50
1,75,700.38
80.64
9,712.00
0.89
2,191
23.05
42.75
1,487.90
1,20,178.85
23.13
28,409.50
7.12
5,291
30.28
49.20
3,519.90
1,19,129.41
62.79
11,539.40
11.59
1,911
10.91
65.81
2,589.50
#5 1,06,876.11
#8 61.82
#7 12,744.20
#2 19.57
#8 2,007
#9 -10.91
58.90
1,265.50
1,05,614.97
#1 18.77
33,741.20
16.73
5,725
1.26
47.24
971.25
97,730.48
20.83
23,511.00
13.82
4,615
-0.19
50.79
1,941.40
88,662.86
27.01
22,909.50
#1 19.94
3,306
#1 112.49
49.98
34,580.00
73,480.09
52.18
6,684.70
10.80
1,414
27.83
60.84
1,114.10
64,707.11
18.78
31,378.10
17.55
3,366
-0.50
43.00

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
19.57 %
Net Income Growth
48.26 %
Cash Flow Change
12.12 %
ROE
18.04 %
ROCE
13.14 %
EBITDA Margin (Avg.)
16.05 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,517
2,998
3,189
3,286
3,333
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,836
2,212
2,227
2,383
2,401
EBITDA
323
476
622
477
467
718
746
681
681
786
962
903
933
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
24 %
28 %
26 %
22 %
Depreciation
47
78
79
85
85
87
97
110
100
108
106
187
231
Interest
13
16
10
13
5
6
9
9
9
11
7
221
191
Profit Before Tax
263
382
533
379
377
625
641
562
572
668
849
495
511
Tax
70
84
110
83
84
130
130
103
95
125
190
111
86
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
425
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.46
10.19

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
9,148
9,715
11,963
27,760
Fixed Assets
3,588
4,251
4,545
19,005
Current Assets
4,407
4,328
6,568
6,988
Capital Work in Progress
702
550
282
826
Investments
1,110
1,346
2,568
2,042
Other Assets
3,749
3,568
4,568
5,887
Total Liabilities
9,148
9,715
11,963
27,760
Current Liabilities
2,624
1,863
2,120
5,664
Non Current Liabilities
208
229
268
7,528
Total Equity
6,316
7,623
9,576
14,568
Reserve & Surplus
6,115
7,395
9,323
14,291
Share Capital
40
40
40
41

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
103
-92
156
22
77
22
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
-12,624
Operating Activities
1,070
1,137
920
1,813
2,152
2,413
Financing Activities
-531
-8
605
-740
5
10,233

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
72.70 %
72.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
12.92 %
13.07 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
11.48 %
11.50 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
1.64 %
1.52 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
1.26 %
1.23 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431
1,80,597
1,79,549

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
07 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
07 Aug 2025 2,386.35 2,600.95
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jul 2025 2,578.00 2,600.95
21 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 May 2025 2,430.05 2,550.70
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 2,738.25 2,515.05
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2024 2,506.95 2,734.95
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 2,114.50 2,068.60

Announcements

Intimation Of Receipt Of Request For Reclassification1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or Depositories6 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Business Responsibility and Sustainability Reporting (BRSR)8 days ago
Reg. 34 (1) Annual Report.8 days ago
Notice Of 34Th Annual General Meeting Of Mankind Pharma Limited8 days ago
Closure of Trading Window9 days ago
Corporate Action-Board to consider Dividend9 days ago
Board Meeting Intimation for Unaudited Quarterly Financial Results & Interim Dividend9 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Intimation Of The Date Of 34Th Annual General Meeting (AGM) Of The CompanyJul 03, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 10, 2025
Intimation Under Regulations 30 & 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Environmental Social And Governance (ESG) RatingJun 04, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 21, 2025
Appointment Of Cost Auditor And Secretarial AuditorMay 21, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMay 21, 2025
Outcome Of Board MeetingMay 21, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 21, 2025
Outcome Of Board MeetingMay 21, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 15, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 14, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 11, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 09, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 50 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 08, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2025
Release Of Pledge On The Shares Of Bharat Serums And Vaccines Limited A Wholly Owned Subsidiary Of The CompanyMay 02, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 14, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On April 14 2025Apr 14, 2025
Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017) Apr 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationMar 29, 2025
Effective Date Of The Scheme Of Arrangement For Amalgamation Amongst Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedMar 29, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementMar 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMar 25, 2025

Technical Indicators

RSI(14)
Neutral
60.12
ATR(14)
Volatile
75.38
STOCH(9,6)
Neutral
67.70
STOCH RSI(14)
Neutral
45.34
MACD(12,26)
Bullish
10.12
ADX(14)
Strong Trend
36.27
UO(9)
Bearish
43.21
ROC(12)
Uptrend And Accelerating
7.82
WillR(14)
Neutral
-33.12

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
4.20%
675397
2.58%
2.47%
Kotak Arbitrage Fund Direct-Growth
0.06%
154125
0.05%
0.06%
Sundaram Mid Cap Fund Direct-Growth
0.99%
78258
0.05%
0.04%
Canara Robeco Multi Asset Allocation Fund Direct-Growth
1.12%
44370
1.12%
1.12%
Union Multicap Fund Direct - Growth
0.00%
-41033
-0.90%
-0.95%
Edelweiss Large Cap Fund Direct -Growth
0.00%
-35943
-0.70%
-0.72%
Aditya Birla Sun Life Arbitrage Fund Direct-Growth
0.04%
34875
0.04%
0.04%
Sundaram Aggressive Hybrid Fund Direct-Growth
0.71%
29000
0.04%
0.01%
Bandhan Flexi Cap Fund Direct-Growth
1.14%
25000
-0.03%
0.11%
Invesco India Arbitrage Fund Direct-Growth
0.02%
18675
0.02%
0.02%
Bandhan Large & Mid Cap Fund Direct-Growth
0.85%
18537
-0.06%
-0.14%
ITI Large Cap Fund Direct - Growth
0.47%
-16500
-0.80%
-0.85%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.60%
-14534
-0.20%
-0.28%
Axis Multicap Fund Direct-Growth
0.40%
-13385
-0.09%
-0.13%
Sundaram Multi Asset Allocation Fund Direct - Growth
0.63%
13350
0.07%
0.63%
Sundaram Large and Mid Cap Fund Direct-Growth
1.25%
11282
-0.08%
0.06%
Bandhan Midcap Fund Direct-Growth
1.07%
-10972
-0.30%
-0.38%
Union Arbitrage Fund Direct - Growth
0.42%
6075
0.42%
0.42%
Canara Robeco Flexi Cap Fund Direct-Growth
1.17%
6000
-0.12%
-0.16%
Canara Robeco Large Cap Fund Direct-Growth
1.27%
6000
-0.12%
-0.15%
Sundaram Balanced Advantage Fund Direct-Growth
0.60%
6000
0.04%
0.03%
SBI Arbitrage Opportunities Fund Direct-Growth
0.00%
5850
0.00%
0.00%
Edelweiss Arbitrage Fund Direct-Growth
0.01%
4725
0.01%
0.01%
Nippon India Multi Asset Allocation Fund Direct - Growth
0.28%
-3981
-0.05%
-0.07%
UTI Arbitrage Fund Direct-Growth
0.01%
3150
0.01%
0.01%

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years, 15 days)
Chairperson NameRAMESH CHAND JUNEJA